{"type":"trials","record":{"id":41545,"source_id":"clinicaltrials-gov","external_id":"NCT06510816","title":"A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)","brief_summary":"The primary purpose of the study is to determine if IVT injections of vonaprument every month reduce vision loss in participants with dry AMD with GA.","overall_status":"Active Not Recruiting","phases":["PHASE3"],"study_type":"INTERVENTIONAL","sponsor":"Annexon, Inc.","enrollment":659,"countries":["United States","Australia","Austria","Canada","Czechia","France","Germany","Hungary","Italy","Netherlands","New Zealand","Poland","Spain","United Kingdom"],"start_date":"2024-07-30","completion_date":"2027-07-31","last_update_date":"2026-05-04","source_url":"https://clinicaltrials.gov/study/NCT06510816","editorial_summary":"A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"ARCHER II","age_range":"50 Years","comparator":null,"organization":"Annexon, Inc.","interventions":["Vonaprument","Sham Administration"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Proportion of Participants Experiencing a Best Corrected Visual Acuity (BCVA) ≥15-letter Loss from Baseline Through Mon…","Time to Confirmed BCVA ≥15-letter Loss — Baseline to Month 15 and Baseline to Month 24","Proportion of Participants Experiencing a Confirmed BCVA ≥15-letter Loss — Baseline through Month 24","Proportion of Participants with Low-luminance BCVA (LLVA) ≥15-letter Loss — Baseline through Month 15 and Baseline thro…","Change from Baseline in Area of Total Loss of the Ellipsoid Zone (EZ) Layer — Baseline, Month 15 and 24"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","source_has_results":false},"controlled_terms":["Geographic Atrophy","Vonaprument","Sham Administration"],"relevance_confidence":80,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct06510816","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2024-07-30 to 2027-07-31","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.831Z","intervention":["Vonaprument","Sham Administration"],"participants":659,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE3","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Proportion of Participants Experiencing a Best Corrected Visual Acuity (BCVA) ≥15-letter Loss from Baseline Through Mon…","Time to Confirmed BCVA ≥15-letter Loss — Baseline to Month 15 and Baseline to Month 24","Proportion of Participants Experiencing a Confirmed BCVA ≥15-letter Loss — Baseline through Month 24","Proportion of Participants with Low-luminance BCVA (LLVA) ≥15-letter Loss — Baseline through Month 15 and Baseline thro…","Change from Baseline in Area of Total Loss of the Ellipsoid Zone (EZ) Layer — Baseline, Month 15 and 24"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","title context","study type"],"relevance_score":80,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41545","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}